Patient management by Neoral C2 monitoring: An international consensus statement

Transplantation

Volumn 73, Issue 9 SUPPL, 2002, Pages

  Levy, Gary ^a   Thervet, Eric ^a   Lake, John ^a   Uchida, Kazuharu ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEORAL C2;

AREA UNDER THE CURVE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; GRAFT REJECTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RNA TRANSPORT; RUGBY; TRANSPLANTATION; VALIDATION PROCESS;

EID: 0037093525     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200205151-00003     Document Type: Review

References (36)

1. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcomes after kidney transplantation
2. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals
3. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic allograft rejection
4. Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs
5. Pharmacokinetic validation of Neoral absorption profiling
6. The temporal profile of calcineurin inhibition by cyclosporine in vivo
7. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine + rapamycin regimen
8. Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect
9. Approaching the therapeutic window for cyclosporine in kidney transplantation: A prospective study
10. Neoral monitoring by simplified sparse sampling area under the concentration-time curve
11. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy
12. 2 levels is predictive for AUC in lung transplant recipients
13. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring stable pediatric kidney transplant recipients
14. Relationship between cyclosporine microemulsion (Neoral) C-2 levels and exposure in de novo and maintenance pediatric liver transplant recipients
15. max) correlate with freedom from liver graft rejection
16. Effect of "C2" cyclosporine levels and time to initiation of cyclosporine therapy on outcomes in patients receiving Neoral and Simulect
17. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation
18. Monitoring of 2-hour Neoral absorption in renal transplantation shows low incidence of acute rejection in the early post-graft period: Interim results of the MO2ART study
19. Randomized, international study of Neoral absorption profiling in renal transplantation with basiliximab immunoprophylaxis
20. Excellent renal tolerability of Neoral C-2 h monitoring in de novo kidney transplantation: Initial results of the MO2ART trial
21. 2 level monitoring in de novo renal transplant recipients
22. 2)
23. 2 target early on efficacy and safety
24. 2 in liver transplant recipients
25. 2 monitoring are sustained at 1 year in de novo liver transplant recipients
26. Conversion from C-0 to C-2 monitoring may permit optimization of longterm Neoral exposure in stable renal transplant recipients
27. 2 cyclosporine monitoring using Neoral immunosuppression in maintenance liver transplant patients: Improvement in renal function and hypertension
28. Lower cyclosporine exposure increases the risk for subclinical rejection in renal transplant recipients
29. 2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients
30. 2 monitoring strategy for optimising cyclosporin immunosuppression
31. Monitoring of cyclosporine 2-hr post-dose and trough levels in heart transplantation
32. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice
33. An evaluation of the cyclosporine parent-compound-specific whole blood TDx assay
34. Cyclosporin whole blood immunoassays (AxSYM, CEDIA and Emit): A critical overview of performance characteristics and comparison with HPLC
35. 2 levels?